Research programme: Fas inhibitors - Apoxis
Latest Information Update: 23 Nov 2006
At a glance
- Originator Apoxis
- Mechanism of Action Apoptosis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 02 Jul 2003 Preclinical trials in Autoimmune disorders in Switzerland (unspecified route)